NASDAQ:PTCT
PTC Therapeutics Stock News
$40.12
+7.03 (+21.23%)
At Close: May 20, 2024
Investment Analysts Recent Ratings Updates for PTC Therapeutics (PTCT)
12:54am, Wednesday, 17'th Nov 2021 Dakota Financial News
PTC Therapeutics (NASDAQ: PTCT) has recently received a number of price target changes and ratings updates: 11/12/2021 PTC Therapeutics was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of []
PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q3 2021 Results - Earnings Call Transcript
01:43am, Friday, 29'th Oct 2021
PTC Therapeutics' (PTCT) CEO Stuart Peltz on Q3 2021 Results - Earnings Call Transcript
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
06:20pm, Thursday, 28'th Oct 2021
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -6.18% and 16.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics' Rare Genetic Disease Gene Therapy Shows Durable Improvement Even At 5 Years
12:30pm, Wednesday, 29'th Sep 2021
PTC Therapeutics Inc (NASDAQ: PTCT) presented a new analysis of five-year results of gene therapy, PTC-AADC. The data exhibited improvements in children with aromatic L-Amino acid decarboxylase (AA
Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy
08:00am, Wednesday, 29'th Sep 2021
SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented a new analysis of five-year results that shows its novel gene therapy, PTC-AADC, leads to
PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program
04:34pm, Monday, 20'th Sep 2021
SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer stu
SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented real-world results from the STRIDE patient registry demonstrating that treatment with Trans
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
08:00am, Friday, 27'th Aug 2021
SOUTH PLAINFIELD, N.J., Aug. 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Morgan Stanley
PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder
07:06am, Tuesday, 24'th Aug 2021
The Brazilian Health Regulatory Agency has approved PTC Therapeutics Inc's (NASDAQ: PTCT) Waylivra (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS). The approval
PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome
04:30pm, Monday, 23'rd Aug 2021
SOUTH PLAINFIELD, N.J., Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância San
SOUTH PLAINFIELD, N.J., Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, "Gene Therapy in the Putamen for Curing AADC Deficiency an
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2021 Results - Earnings Call Transcript
11:16pm, Thursday, 29'th Jul 2021
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2021 Results - Earnings Call Transcript
Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™
05:00pm, Wednesday, 28'th Jul 2021
SOUTH PLAINFIELD, N.J., July 28, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England J
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results
08:00am, Thursday, 15'th Jul 2021
SOUTH PLAINFIELD, N.J., July 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 fina
Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy
08:00am, Wednesday, 23'rd Jun 2021
SOUTH PLAINFIELD, N.J., June 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Japan by the Japanese Ministry of Health, Labo